Blacksburg, United States
Techulon Inc. is a biotechnology startup founded in 2006. The company is pioneering the next generation of disease treatment with a focus on developing safe and effective treatments for drug-resistant infections. Techulon's approach involves defeating bacteria at the genomic level, resulting in potent drugs that are not susceptible to resistance, setting them apart from current antibiotics on the market.
Utilizing a robust platform, Techulon enables the delivery of nucleic acids for various therapeutic applications. The company's recent milestone includes a $1.9M contract from DARPA, a significant achievement that demonstrates its potential in advancing antimicrobial platforms to combat both Gram-negative and Gram-positive bacteria. Moreover, through a novel informatics approach, Techulon has identified new gene targets and is actively developing antimicrobial therapeutics for broad applications.
The latest investment in Techulon was a Venture Round investment on 31st August 2020, with the Virginia Founders Fund participating as the investor. With its innovative approach to addressing critical medical challenges and ongoing support from investors, Techulon Inc. is positioned as a noteworthy player in the biotechnology industry, poised for further growth and impact within the United States and beyond.
